EUVIMEDEUVIMED entdecken
Crossref

Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas

Nada Shaker, Wei Chen, William Sinclair, Anil V Parwani, Zaibo Li

Modern Pathology · 2023

DOI: 10.1016/j.modpat.2022.100038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023. Verfasst von Nada Shaker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Hauptthemen laut MEDLINE: Hemangiosarcoma, Ovarian Neoplasms, Genital Neoplasms, Female, Endometrial Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Similar to PAX8, SOX17 was recently identified as a master transcription factor of ovarian cancer based on RNA sequencing data. We explored SOX17 utility in diagnosing ovarian tumors and other gynecologic tumors. We systematically evaluated SOX17 expression on tissue microarrays of 398 ovarian tumors of various types, 93 endometrial carcinomas, 80 cervical carcinomas, and 1371 nongynecologic carcinomas, such as those of kidney, thyroid, breast, colon, bladder, liver, bile duct, adrenal gland, pancreas, brain, and lung and malignant melanoma. In addition, we evaluated SOX17 expression in whole tissue sections from 60 gynecologic carcinomas and 10 angiosarcomas. The results demonstrated that SOX17 was highly expressed in most ovarian and endometrial tumors with strong intensity. However, unlike PAX8, it was predominately negative in other tested tumor types, including kidney and thyroid tumors. In particular, SOX17 was highly expressed in the following pathologic subtypes of ovarian tumors: serous carcinoma, clear cell carcinoma, endometrioid carcinoma, and germ cell tumors. SOX17 was mostly negative in mucinous carcinoma and sex cord stromal tumors. In addition, SOX17 was expressed in vascular endothelial cells and was positive in all tested angiosarcomas. In summary, our results demonstrate that SOX17 is a sensitive and specific marker for ovarian nonmucinous carcinomas and endometrial carcinomas. For ovarian germ cell tumors and angiosarcomas, SOX17 demonstrates higher specificity than PAX8, with comparable sensitivity. Furthermore, SOX17 positivity in endothelial cells serves as an internal positive control, making it an excellent marker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiosarcomaOvarian NeoplasmsGenital Neoplasms, FemaleEndometrial NeoplasmsAdenocarcinoma, MucinousHumansFemalePaired Box Transcription FactorsPAX8 Transcription FactorEndothelial CellsBiomarkers, TumorImmunohistochemistrySOXF Transcription Factors

Stichwörter der Autor:innen

PAX8SOX17biomarkergynecologic tumorsnongynecologic tumors

Substanzen

Paired Box Transcription FactorsPAX8 Transcription FactorBiomarkers, TumorSOX17 protein, humanSOXF Transcription Factors

Autor:innen und Institutionen

  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: Zaibo.Li@osumc.edu.

Zitieren

APA

Shaker, N., Chen, W., Sinclair, W., Parwani, A. V., & Li, Z. (2023). Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas. Modern Pathology. https://doi.org/10.1016/j.modpat.2022.100038

Vancouver

Shaker N, Chen W, Sinclair W, Parwani AV, Li Z. Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas. Modern Pathology. 2023. doi:10.1016/j.modpat.2022.100038

BibTeX
@article{Shaker2023,
  author = {Shaker, Nada and Chen, Wei and Sinclair, William and Parwani, Anil V and Li, Zaibo},
  title = {Identifying SOX17 as a Sensitive and Specific Marker for Ovarian and Endometrial Carcinomas},
  journal = {Modern Pathology},
  year = {2023},
  doi = {10.1016/j.modpat.2022.100038}
}
Kostenlos starten →